These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 20948291)
1. Antibody immunosuppressive therapy in solid organ transplant: Part II. Klipa D; Mahmud N; Ahsan N MAbs; 2010; 2(6):607-12. PubMed ID: 20948291 [TBL] [Abstract][Full Text] [Related]
2. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Webster AC; Wu S; Tallapragada K; Park MY; Chapman JR; Carr SJ Cochrane Database Syst Rev; 2017 Jul; 7(7):CD004756. PubMed ID: 28731207 [TBL] [Abstract][Full Text] [Related]
3. [Monoclonal antibodies in organ transplantation]. Vanhove B Med Sci (Paris); 2009 Dec; 25(12):1121-5. PubMed ID: 20035690 [TBL] [Abstract][Full Text] [Related]
4. Current status of immunosuppressive agents for solid organ transplantation in children. Coelho T; Tredger M; Dhawan A Pediatr Transplant; 2012 Mar; 16(2):106-22. PubMed ID: 22360399 [TBL] [Abstract][Full Text] [Related]
5. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178 [TBL] [Abstract][Full Text] [Related]
6. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Wilde MI; Goa KL Drugs; 1996 May; 51(5):865-94. PubMed ID: 8861551 [TBL] [Abstract][Full Text] [Related]
7. The use of basiliximab in solid organ transplantation. Henry ML; Rajab A Expert Opin Pharmacother; 2002 Nov; 3(11):1657-63. PubMed ID: 12437498 [TBL] [Abstract][Full Text] [Related]
8. Induction therapy: why, when, and which agent? Krischock L; Marks SD Pediatr Transplant; 2010 May; 14(3):298-313. PubMed ID: 20345609 [TBL] [Abstract][Full Text] [Related]
10. Daclizumab: a review of its use in the management of organ transplantation. Carswell CI; Plosker GL; Wagstaff AJ BioDrugs; 2001; 15(11):745-73. PubMed ID: 11707149 [TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status. Swiatecka-Urban A Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627 [TBL] [Abstract][Full Text] [Related]
12. Basiliximab: a review of its use as induction therapy in renal transplantation. Chapman TM; Keating GM Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658 [TBL] [Abstract][Full Text] [Related]
13. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial. Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187 [TBL] [Abstract][Full Text] [Related]
14. Innate immunity in solid organ transplantation: an update and therapeutic opportunities. Béland S; Désy O; Vallin P; Basoni C; De Serres SA Expert Rev Clin Immunol; 2015 Mar; 11(3):377-89. PubMed ID: 25644774 [TBL] [Abstract][Full Text] [Related]
15. Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors. Alegre ML; Lenschow DJ; Bluestone JA Dig Dis Sci; 1995 Jan; 40(1):58-64. PubMed ID: 7821120 [TBL] [Abstract][Full Text] [Related]
16. Muromonab CD3. A review of its pharmacology and therapeutic potential. Todd PA; Brogden RN Drugs; 1989 Jun; 37(6):871-99. PubMed ID: 2503348 [TBL] [Abstract][Full Text] [Related]
17. New insights into therapy with monoclonal antibodies in allograft transplantation. Schena FP Nephrol Dial Transplant; 1997; 12 Suppl 1():55-8. PubMed ID: 9075230 [No Abstract] [Full Text] [Related]